3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
216
Stomach Neoplasms
166
Rectal Neoplasms
146
Pancreatic Neoplasms
81
Colonic Neoplasms
77
Neoplasm Metastasis
67
Esophageal Neoplasms
55
Neoplasms
31
Adenocarcinoma Of Esophagus
29
Cholangiocarcinoma
28
Carcinoma, Hepatocellular
26
Adenocarcinoma
26
Biliary Tract Neoplasms
23
Lymphoma, Large B-Cell, Diffuse
19
Recurrence
17
Carcinoma, Non-Small-Cell Lung
16
Gallbladder Neoplasms
14
Breast Neoplasms
14
Head and Neck Neoplasms
11
Locally Advanced Rectal Cancer
10
Liver Neoplasms
10
Gastrointestinal Neoplasms
10
Esophageal Squamous Cell Carcinoma
9
Peritoneal Neoplasms
8
Ovarian Neoplasms
8
Colorectal Cancer Metastatic
7
Bile Duct Neoplasms
6
Urinary Bladder Neoplasms
5
Lymphoma, Non-Hodgkin
5
Lymphoma, Extranodal NK-T-Cell
5
Interventions
Cyclophosphamide
3
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
liposomal doxorubicin
2
Paclitaxel
2
Gemcitabine
2
Doxorubicin
2
Dexamethasone
2
Cisplatin
2
Carboplatin
2
Bortezomib
2
vandetanib
1
umbralisib
1
ublituximab
1
regorafenib
1
pomalidomide
1
pembrolizumab
1
nilotinib
1
marizomib
1
lutetium Lu 177 dotatate
1
grapiprant
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
cemiplimab
1
carotuximab
1
axicabtagene ciloleucel
1
avelumab
1
Thioctic Acid
1
Tamoxifen
1
Receptors, Interleukin-6
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Disease Progression
×
Oxaliplatin
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts